Skip to content
myglp1coverage.com

BCBS North Dakota · Weight Loss

BCBS North Dakota coverage for Wegovy (Weight Loss)

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • BMI of 30 or higher
  • BMI of 27 or higher with a weight-related condition (HTN, T2DM, dyslipidemia, OSA, and CVD)
  • BMI of 25 or higher for patients of Asian descent
  • 6 months of a documented diet and exercise program

Qualification pathways

You can qualify through any one of these.

Adult obesity without comorbidity

All of:

  • BMI >= 30 kg/m2 (or >= 25 kg/m2 for South Asian, Southeast Asian, or East Asian adults)
  • Inadequate response to comprehensive lifestyle intervention program

Adult overweight with comorbidity

All of:

  • BMI >= 27 kg/m2 (or >= 23 kg/m2 for South Asian, Southeast Asian, or East Asian adults)
  • Inadequate response to comprehensive lifestyle intervention program

Plus any one of:

  • Hypertension
  • Type 2 diabetes
  • Dyslipidemia
  • Obstructive sleep apnea
  • Cardiovascular disease
  • Other weight-related comorbid condition

Pediatric (age >= 12) obesity

All of:

  • Age >= 12 years
  • Body weight > 60 kg
  • Obesity diagnosis

Documentation to bring

  • Documentation of BMI >= 30 kg/m2 or >= 27 kg/m2 with at least one weight-related comorbidity
  • Documentation of prior comprehensive lifestyle intervention program attempt or reason it is not feasible
  • Documentation of weight-related comorbid condition if BMI is 27-29.9 kg/m2

Approval and renewal

  • To renew, the plan looks for at least 5% weight loss from the starting weight, Per referenced guidelines, if weight loss >= 5% of body weight at 3 months, medication should be continued. If weight loss < 5% at 3 months or safety/tolerability issues, medication should be discontinued, and at least 12 weeks on therapy before the first renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Coadministration with other semaglutide-containing products is not recommended
  • Coadministration with any other GLP-1 receptor agonist is not recommended

Policy note: Document is a program summary with clinical rationale referencing AHA/ACC/Obesity Society 2013 guidelines, AACE/ACE guidelines, Endocrine Society guidelines, and AGA 2022 guidelines. Full PA criteria details (specific approval criteria, quantity limits) are not fully enumerated in the provided document text. Asian BMI threshold of 23 kg/m2 referenced in AACE guidelines cited within the document for South Asian, Southeast Asian, and East Asian adults. Wegovy is available as both subcutaneous injection and tablet formulations per FDA indications listed. Pediatric indication applies to ages >= 12 with body weight > 60 kg.

Policy effective April 20, 2026 · verified June 2, 2026 · source: ND_Weight_Management_PAQL_ProgSum.pdf

ACA Marketplace

Covered with requirements

What you need to qualify

  • BMI of 30 or higher
  • BMI of 27 or higher with a weight-related condition (HTN, T2DM, dyslipidemia, OSA, and CVD)
  • BMI of 25 or higher for patients of Asian descent
  • 6 months of a documented diet and exercise program

Qualification pathways

You can qualify through any one of these.

Adult obesity without comorbidity

All of:

  • BMI >= 30 kg/m2 (or >= 25 kg/m2 for South Asian, Southeast Asian, or East Asian adults)
  • Inadequate response to comprehensive lifestyle intervention program

Adult overweight with comorbidity

All of:

  • BMI >= 27 kg/m2 (or >= 23 kg/m2 for South Asian, Southeast Asian, or East Asian adults)
  • Inadequate response to comprehensive lifestyle intervention program

Plus any one of:

  • Hypertension
  • Type 2 diabetes
  • Dyslipidemia
  • Obstructive sleep apnea
  • Cardiovascular disease
  • Other weight-related comorbid condition

Pediatric (age >= 12) obesity

All of:

  • Age >= 12 years
  • Body weight > 60 kg
  • Obesity diagnosis

Documentation to bring

  • Documentation of BMI >= 30 kg/m2 or >= 27 kg/m2 with at least one weight-related comorbidity
  • Documentation of prior comprehensive lifestyle intervention program attempt or reason it is not feasible
  • Documentation of weight-related comorbid condition if BMI is 27-29.9 kg/m2

Approval and renewal

  • To renew, the plan looks for at least 5% weight loss from the starting weight, Per referenced guidelines, if weight loss >= 5% of body weight at 3 months, medication should be continued. If weight loss < 5% at 3 months or safety/tolerability issues, medication should be discontinued, and at least 12 weeks on therapy before the first renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Coadministration with other semaglutide-containing products is not recommended
  • Coadministration with any other GLP-1 receptor agonist is not recommended

Policy note: Document is a program summary with clinical rationale referencing AHA/ACC/Obesity Society 2013 guidelines, AACE/ACE guidelines, Endocrine Society guidelines, and AGA 2022 guidelines. Full PA criteria details (specific approval criteria, quantity limits) are not fully enumerated in the provided document text. Asian BMI threshold of 23 kg/m2 referenced in AACE guidelines cited within the document for South Asian, Southeast Asian, and East Asian adults. Wegovy is available as both subcutaneous injection and tablet formulations per FDA indications listed. Pediatric indication applies to ages >= 12 with body weight > 60 kg.

Policy effective April 20, 2026 · verified June 2, 2026 · source: ND_Weight_Management_PAQL_ProgSum.pdf

All Wegovy policies under BCBS North Dakota · Check your card